Discovery of a Novel Non-Peptide Somatostatin Agonist with SST4 Selectivity
摘要:
The discovery of novel non-peptide compounds with a high affinity for the peptide hormone somatostatin (SST) receptor is described. The compounds were tested for affinity at five human SST receptor subtypes individually expressed in mammalian cells. The compound NNC 26-9100 showed a K-i of 6 nM at SST4 and more than 100 fold selectivity for SST4 over SST1, SST2, SST3, or SST5. Competition binding studies and Scatchard analysis of the interaction by NNC 26-9100 with SST showed specificity at SST4. Furthermore, NNC 26-9100 was highly selective for SST4 over a variety of other G protein-coupled receptors, having affinities for M-1 muscarinic acetylcholin and D-3 dopamine receptors of around 500 and 1000 nM, respectively. Finally, NNC 26-9100 was found to fully inhibit forskolin-induced accumulation of adenosine 3',5'-cyclic monophosphate in baby hamster kidney cells, expressing the human SST4 receptor with an EC50 of 2 nM.
Pyridyl substituted aminoalkyl-thioureas and ureas
申请人:Smith Kline & French Laboratories, Inc.
公开号:US03932427A1
公开(公告)日:1976-01-13
The compounds are pyridyl substituted aminoalkylthioureas and ureas which are inhibitors of H-2 histamine receptors. A compound of this invention is N-methyl-N'-[2-(2-pyridylmethylamino)ethyl]thiourea.
BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS
申请人:Gilead Sciences, Inc.
公开号:US20160333009A1
公开(公告)日:2016-11-17
The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I:
or pharmaceutically acceptable salts thereof, in which X, L, n, m, R
1
, R
2a
, R
2b
, R
n
, R
m
, and R
t
are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.
本公开提供了式I的吲哌酮2,3-二氧化酶1(IDOL)抑制剂:
或其药学上可接受的盐,其中X、L、n、m、R
1
、R
2a
、R
2b
、R
n
、R
m
和R
t
如本文所定义,以及包括式I化合物的药物组合物,或其药学上可接受的盐,并使用这些方法来治疗由IDO1介导的疾病。
Synthesis and Functional Characterization of Imbutamine Analogs as Histamine H<sub>3</sub>and H<sub>4</sub>Receptor Ligands
EC50 = 59 nM, α = 0.8) was equipotent with imbutamine at the hH4R, but revealed about 16‐fold selectivity for the hH4R compared to the hH3R (EC50 980 nM, α = 0.36), whereas imbutamine preferred the hH3R. The functional activities were in agreement with radioligand binding data. The results support the hypothesis that, by analogy with histamine, methyl substitution in histamine homologs offers a way to shift the
The invention relates to novel compounds which bind to integrin receptors, and to the preparation thereof and the use thereof as drugs.
这项发明涉及结合到整合素受体的新化合物,以及其制备和作为药物的用途。
Synthesis of Selectively Mono-N-Arylated Aliphatic Diamines<i>via</i>Iridium-Catalyzed Amine Alkylation
作者:Benoît Blank、Stefan Michlik、Rhett Kempe
DOI:10.1002/adsc.200900548
日期:2009.11
A highly selective phosphorus/nitrogen (P,N) ligand-based iridium catalyst system efficiently catalyzes the reaction of arylamines with unprotected amino alcohols, yielding N-arylated aliphatic diamines in yields of up to 93%. The reaction can be performed with a wide variety of branched and linear amino alcohols in combination with various aminopyridines or substituted anilines.